Lumos Diagnostics (ASX:LDX) Secures Additional Medicare Coverage
Reimbursement Coverage
Lumos Diagnostics has secured Medicare reimbursement for FebriDx from two additional Medicare Administrative Contractors, FCSO and Noridian, at US$41.38 per test, retroactive from 1 April 2025. This brings US reimbursement coverage to four of seven MACs, representing over 55% of US Medicare payment coverage.
Executive Comments
Doug Ward, Managing Director of Lumos Diagnostics said: “Securing additional Medicare coverage from FCSO and Noridian for FebriDx reinforces our commitment to developing a point-of-care diagnostic solution that not only benefits patients, but also integrates seamlessly into care pathways and delivers value to the broader health system.”
“Lumos remains committed to securing adoption from the remaining three MACs and pursuing reimbursement coverage from private payors, with the goal of achieving nationwide access for patients and supporting broad clinical adoption of FebriDx.”
Motley Fool contributor Kiarra Jackson has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
